Literature DB >> 31002430

Long-term outcome of inpatients with bulimia nervosa-Results from the Christina Barz Study.

Norbert Quadflieg1, Manfred M Fichter1,2.   

Abstract

OBJECTIVE: To assess the long-term outcome and identify outcome predictors in a very large sample of inpatients treated for bulimia nervosa (BN).
METHOD: Out of a total of 2,033 patients admitted consecutively to specialized treatment, 1,351 patients (mean age at treatment 25.94) were assessed for follow-up on average 11 (SD 6) years after admission. Also a very long-term (21 years) subsample (N = 147; mean age 25.92) was defined. Bivariate and logistic regression analyses identified predictors of poor outcome.
RESULTS: For more than 70% of the patients follow-up information could be gathered. Severity of eating disorder (ED) and other symptoms decreased over time but remained higher than in healthy controls, using published normative data. Remission rate was 38% after 11 years and 42% in the subsample after 21 years. Out of the total sample of N = 2,033 patients, 49 had died (2.4%). Persistent BN was found in 14.2% and the most frequent crossover was to ED not otherwise specified. Predictors of poor outcome were fewer follow-up years, higher drive for thinness, higher age at treatment, and less global functioning. DISCUSSION: Based on clinical indicators, patients presented with a high level of ED and psychiatric symptomatology. With less than half of the patients remitted after 22 years, efforts are needed to improve treatment outcome.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  bulimia nervosa; course; eating disorders; long-term; mortality; outcome

Year:  2019        PMID: 31002430     DOI: 10.1002/eat.23084

Source DB:  PubMed          Journal:  Int J Eat Disord        ISSN: 0276-3478            Impact factor:   4.861


  8 in total

1.  Remission in adolescents with bulimia nervosa: Empirical evaluation of current conceptual models.

Authors:  Sasha Gorrell; Brittany E Matheson; James Lock; Daniel Le Grange
Journal:  Eur Eat Disord Rev       Date:  2020-03-04

2.  Therapists' Experiences of Working with Ethnic Minority Females with Eating Disorders: A Qualitative Study.

Authors:  Natalie Kanakam
Journal:  Cult Med Psychiatry       Date:  2021-05-12

3.  Detection, treatment, and course of eating disorders in Finland: A population-based study of adolescent and young adult females and males.

Authors:  Yasmina Silén; Pyry N Sipilä; Anu Raevuori; Linda Mustelin; Mauri Marttunen; Jaakko Kaprio; Anna Keski-Rahkonen
Journal:  Eur Eat Disord Rev       Date:  2021-05-18

Review 4.  A systematic review of cognitive behavior therapy and dialectical behavior therapy for adolescent eating disorders.

Authors:  Emily N Vogel; Simar Singh; Erin C Accurso
Journal:  J Eat Disord       Date:  2021-10-18

5.  Applying a web-based self-help intervention for bulimia nervosa in routine care: Study protocol for a randomized controlled trial.

Authors:  Steffen Hartmann; Luise Pruessner; Julian A Rubel; Christopher Lalk; Sven Barnow; Christina Timm
Journal:  Internet Interv       Date:  2022-02-17

6.  Changes in cognitive and behavioral control after lamotrigine and intensive dialectical behavioral therapy for severe, multi-impulsive bulimia nervosa: an fMRI case study.

Authors:  Laura A Berner; Erin E Reilly; Xinze Yu; Angeline Krueger; Mary Ellen Trunko; Leslie K Anderson; Joanna Chen; Alan N Simmons; Walter H Kaye
Journal:  Eat Weight Disord       Date:  2021-10-18       Impact factor: 3.008

7.  Initial self-blame predicts eating disorder remission after 9 years.

Authors:  Suzanne Petersson; Andreas Birgegård; Lars Brudin; Emma Forsén Mantilla; Elin Monell; David Clinton; Caroline Björck
Journal:  J Eat Disord       Date:  2021-07-07

Review 8.  Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions.

Authors:  Anya Ragnhildstveit; Matthew Slayton; Laura Kate Jackson; Madeline Brendle; Sachin Ahuja; Willis Holle; Claire Moore; Kellie Sollars; Paul Seli; Reid Robison
Journal:  Brain Sci       Date:  2022-03-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.